Q17: Is this medical advice
Bibcode:1980PNAS...77.5754S
Calabrese V, Giuffrida Stella AM, Calvani M, Butterfield DA
There is an increased prevalence in women and Asian, African American, and Indian races (Figure 7-12)
Significant, life-transforming weight loss isn't confined to medication alone
GLP1 + Cagrilintide Research Administration Common Study Populations Clinical trials have enrolled diverse participant groups: Adults with obesity BMI 30 kg/m squared or greater without diabetes (REDEFINE 1) Adults with overweight and comorbidities BMI 27 kg/m squared or greater with at least one weight-related condition Adults with type 2 diabetes BMI 27 kg/m squared or greater with established diabetes (REDEFINE 2) Age range Primarily adults aged 18-75 years across trials Geographic diversity Multi-national trials across North America, Europe, Asia, and other regions Exclusion criteria typically included type 1 diabetes, recent cardiovascular events, severe renal or hepatic impairment, history of pancreatitis, and medications causing significant weight changes